Tonix Pharma (TNXP) has released an update.
Tonix Pharmaceuticals Holding Corp. has announced the engagement of Rho, Inc. to assist with the New Drug Application for Tonmya™, aimed at treating fibromyalgia. This move signals progress in the product’s path towards seeking FDA approval. The announcement also contains forward-looking statements, cautioning investors about the inherent risks and uncertainties in the pharmaceutical development process, which could impact the company’s future results and the realization of projected outcomes.
For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.
